Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $55.00 Price Target at Robert W. Baird

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target hoisted by Robert W. Baird from $50.00 to $55.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

Other equities analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $57.60.

Mirum Pharmaceuticals Price Performance

MIRM opened at $46.97 on Thursday. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -23.25 and a beta of 0.96. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $54.23. The firm’s fifty day moving average price is $46.84 and its two-hundred day moving average price is $43.35.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. As a group, analysts anticipate that Mirum Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Peter Radovich sold 2,627 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $126,673.94. Following the transaction, the chief operating officer now directly owns 26,961 shares in the company, valued at $1,300,059.42. This trade represents a 8.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the completion of the transaction, the chief executive officer now directly owns 119,359 shares in the company, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,915 shares of company stock worth $1,897,920 in the last 90 days. 22.87% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MIRM. GF Fund Management CO. LTD. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Mirum Pharmaceuticals by 16.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 73,888 shares of the company’s stock valued at $3,055,000 after acquiring an additional 10,427 shares during the last quarter. Woodline Partners LP boosted its holdings in shares of Mirum Pharmaceuticals by 22.2% during the fourth quarter. Woodline Partners LP now owns 404,404 shares of the company’s stock worth $16,722,000 after purchasing an additional 73,399 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth about $897,000. Finally, Tema Etfs LLC purchased a new position in Mirum Pharmaceuticals during the 4th quarter valued at about $1,735,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.